Inspired by this observation, we have recently repurposed empagliflozin, one of the available SGLT2-inhibitors, to treat neutropenia and neutrophil dysfunction in GSD1b and G6PC3-deficient patients. This evidence concerns the gene G6PC3 and neutropenia.